COST EFFECTIVENESS OF ONASEMNOGENE ABEPARVOVEC IN INFANTS WITH PRESYMPTOMATIC SPINAL MUSCULAR ATROPHY IN ITALY

被引：0
|
作者：
Valentini, I [1 ,2 ]
Ghetti, G. [3 ]
Pane, M. [4 ]
Cicchetti, A. [1 ,2 ]
Rumi, F. [5 ]
Di Brino, E. [1 ,2 ]
Basile, M. [5 ]
Pistillo, G. [6 ]
Bischof, M. [7 ]
机构：
[1] Cattolica Sacro Cuore Univ UCSC, Fac Econ, Rome, Italy
[2] Cattolica Sacro Cuore Univ, Grad Sch Hlth Econ & Management ALTEMS, Rome, Italy
[3] AdRes HEOR, Turin, To, Italy
[4] Fdn Policlin Univ Agostino Gemelli, Rome, Italy
[5] Univ Cattolica Sacro Cuore, Grad Sch Hlth Econ & Management ALTEMS, Rome, Italy
[6] Novartis Gene Therapies, Legnano, MI, Italy
[7] Novartis Gene Therapies GmbH, Rotkreuz, Switzerland
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
RWD129
引用
收藏
页码：S528 / S529
页数：2
相关论文
共 50 条
  • [1] Onasemnogene Abeparvovec for Presymptomatic Infants with Spinal Muscular Atrophy and Two Copies of SMN2
    Strauss, Kevin
    Muntoni, Francesco
    Farrar, Michelle
    Saito, Kayoko
    Mendell, Jerry
    Servals, Laurent
    McMillan, Hugh
    Finkel, Richard
    Swoboda, Kathryn
    Kwon, Jennifer
    Zaidman, Craig
    Chiriboga, Claudia
    Iannaccone, Susan
    Krueger, Jena
    Parsons, Julie
    Shieh, Perry
    Kavanagh, Sarah
    Chand, Deepa
    Tauscher-Wisniewski, Sitra
    McGill, Bryan
    Macek, Thomas
    NEUROLOGY, 2022, 98 (18)
  • [2] Onasemnogene-abeparvovec administration to premature infants with spinal muscular atrophy
    Brown, Stephen M.
    Ajjarapu, Aparna S.
    Ramachandra, Divya
    Blasco-Perez, Laura
    Costa-Roger, Mar
    Tizzano, Eduardo F.
    Sumner, Charlotte J.
    Mathews, Katherine D.
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2024, 11 (11): : 3042 - 3046
  • [3] Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy
    Hannah A. Blair
    CNS Drugs, 2022, 36 : 995 - 1005
  • [4] Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy
    Blair, Hannah A.
    CNS DRUGS, 2022, 36 (09) : 995 - 1005
  • [5] Onasemnogene abeparvovec for the treatment of spinal muscular atrophy
    McMillan, Hugh J.
    Proud, Crystal M.
    Farrar, Michelle A.
    Alexander, Ian E.
    Muntoni, Francesco
    Servais, Laurent
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (09) : 1075 - 1090
  • [6] Onasemnogene abeparvovec for spinal muscular atrophy: The costlier drug ever
    Mahajan, Rajiv
    INTERNATIONAL JOURNAL OF APPLIED AND BASIC MEDICAL RESEARCH, 2019, 9 (03) : 127 - 128
  • [7] Real-world data on the effectiveness and safety of onasemnogene abeparvovec in spinal muscular atrophy
    Weiss, C.
    Becker, L.
    Garbade, S.
    Johannsen, J.
    Ziegler, A.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [8] An evaluation of onasemnogene abeparvovec for spinal muscular atrophy (SMN1)
    Waldrop, Megan A.
    Connolly, Anne M.
    Mendell, Jerry R.
    EXPERT OPINION ON ORPHAN DRUGS, 2021, 9 (7-10): : 199 - 204
  • [9] Cost-Effectiveness of Onasemnogene Abeparvovec Compared With Nusinersen and Risdiplam in Patients With Spinal Muscular Atrophy Type 1 in Brazil
    Fernandes, Brigida Dias
    Rodrigues, Fernanda D'Athayde
    Cirilo, Herica Nubia Cardoso
    Borges, Stefani Sousa
    Krug, Barbara Correa
    Probst, Livia Fernandes
    Zimmermann, Ivan
    VALUE IN HEALTH REGIONAL ISSUES, 2024, 40 : 108 - 117
  • [10] Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy
    D'Silva, Arlene M.
    Holland, Sandra
    Kariyawasam, Didu
    Herbert, Karen
    Barclay, Peter
    Cairns, Anita
    MacLennan, Suzanna C.
    Ryan, Monique M.
    Sampaio, Hugo
    Smith, Nicholas
    Woodcock, Ian R.
    Yiu, Eppie M.
    Alexander, Ian E.
    Farrar, Michelle A.
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2022, 9 (03): : 339 - 350
12345